SAN DIEGO--Genta Jago, a joint venture between Genta Incorporated
and Jagotec AG (Hergiswil, Switzerland), has filed an Investigational
New Drug application with the FDA for a controlled-release formulation
of zidovudine (AZT), marketed by Burroughs Wellcome Co. as Retrovir.
The recommended dosage for AZT in the United States is six times
daily. Results of pilot in vitro and human pharmacokinetic studies
in Europe suggest that once- or twice-daily dosing may be possible
with the controlled-release formulation, which incorporates Jagotec's
Geomatrix delivery technology.